Selected late-stage milestones and potential regulatory events in the first half of 1998

Company Product Indication Milestone
Advanced Tissue Sciences (ATIS) Dermagraft Diabetic foot ulcers FDA panel meeting Jan. 29
Amgen (AMGN) Stemgen (SCF) Peripheral blood progenitor cell stimulator Under FDA review
Aviron (AVIR) Intranasal flu vaccine Prevent flu PLA filing mid-98
BioChem Pharma (BCHE) Lamivudine Hepatitis B Glaxo filings for market approval
BioTime (BTIM) Hextend Replace blood volume lost in surgery Present Phase III data in January
British Biotech (LSE:BBG) Zacutex lexipafant Acute pancreatitis Under European review